Drug industry and health care reform
Executive Summary
Congressional staffers say representatives from individual companies have expressed an eagerness to cooperate in the legislative process. Several firms have offered to support a national prescription drug benefit. PMA's current position endorses a government-funded benefit for the poor, elderly and disabled. Merck has scheduled a briefing in Washington for securities analysts on Jan. 15 to explain its health legislative policies for the new Congress. The firm supports broad prescription drug coverage and payment of royalties to the government for drugs developed with government funding. It opposes global spending limits on health care or price controls.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth